DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20202672

Eruptive xanthomas: a warning sign of future hyperlipidemia complications

Trevor A. Nessel, Connor C. Kerndt, John A. Bills, Lynn Sikorski

Abstract


Eruptive xanthomas are localized lipid deposits in the skin or subcutaneous tissue that are associated with both primary and secondary hyperlipidemia. Typical presentation manifests as small yellow papules on the buttocks or extensor surfaces. Xanthomas can be diagnosed clinically with an extensive history and physical examination, however, can be confirmed via biopsy and histological findings. It is essential to identify the underlying cause of the skin lesions and take appropriate measures to prevent future hyperlipidemia-induced consequences. Here we report a 42-year-old female with eruptive xanthomas on her trunk and extremities. Previous visits to the primary care provider and emergency department resulted in diagnoses of viral exanthems. The consulted dermatologist ordered laboratory tests remarkable for extreme hypertriglyceridemia, hypercholesterolemia, and hyperglycemia. Lifestyle modification in conjunction with cholesterol and triglyceride lowering medications led to the resolution of abnormal laboratory findings and remission of eruptive xanthoma lesions.


Keywords


Eruptive xanthoma, Hypertriglyceridemia, Hypercholesterolemia, Hyperglycemia, Hyperlipidemia

Full Text:

PDF

References


Parker F, Bagdade JD, Odland GF, Bierman EL. Evidence for the chylomicron origin of lipids accumulating in diabetic eruptive xanthomas: a correlative lipid biochemical, histochemical, and electron microscopic study. J Clin Invest. 1970;49(12):2172-87.

Zak A, Zeman M, Slaby A, Vecka M. Xanthomas: Clinical and pathophysiological relations. Biomed Pap. 2014;158(2):181-8.

Christoffersen M, Schmidt FR, Schnohr P, Jensen GB, Nordestgaard BG, Hansen TA. Xanthelasmata, arcus corneae, and ischaemic vascular disease and death in general population: Prospective cohort study. BMJ. 2011;343(7826).

Wheeler DC, Bernard DB. Lipid Abnormalities in the Nephrotic Syndrome: Causes, Consequences, and Treatment. Am J Kidney Dis. 1994;23(3):331-46.

Appel G. Lipid abnormalities in renal disease. Kidney Int. 1991;39(1):169-83.

Love JR, Dubin HV. Xanthomas and lipoproteins. Cutis. 1978;21(6):801-5.

Xanthoma - an overview Science Direct Topics. Available at https://www.sciencedirect.com/topics/medicine-and-dentistry/xanthoma/pdf.

Duzayak S, Sayiner ZA, Erklllc S, Inaloz HS. Acute pancreatitis with eruptive xanthoma. BMJ Case Rep. 2017;2017.

Brunzell JD. Hypertriglyceridemia. N Engl J Med. 2007;357(10):1009-17.

Chang HY, Ridhy TW, Kimball AB, Hughes E, Oro AE. Eruptive xanthomas associated with olanzapine use. Arch Dermatol. 2003;139(8):1045-8.

Duff M, Demidova O, Blackburn S, Shubrook J. Cutaneous manifestations of diabetes mellitus. Clin Diabetes. 2015;33(1):40-8.

Binic I, Jankovic A. Eruptive xanthomas associated with diabetes mellitus. Chin Med J (Engl). 2009;122(17):2074-5.

Richardson T, Aslibekyan S, Ashraf AP. Clinical characteristics and sequelae of severe hypertriglyceridemia in pediatrics. Endocr Pract. 2018;24(9):789-95.

Yamamoto T, Matsuda J, Dateki S, Ouchi K, Fujimoto W. Numerous intertriginous xanthomas in infant: A diagnostic clue for sitosterolemia. J Dermatol. 2016;43(11):1340-4.

Koh XQ, Chandran NS. Eruptive Xanthomas. J Pediatr. 2018;201:295.

Chait A, Subramanian S. Hypertriglyceridemia: Pathophysiology, Role of Genetics, Consequences, and Treatment. MD Text.com, Inc.; 2000. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26561703. Accessed on 3 January 2020.

Yuan G, Shali AKZ, Hegele RA. Hypertriglyceridemia: Its etiology, effects and treatment. CMAJ. 2007;176(8):1113-20.

Pedersen BK, Saltin B. Evidence for prescribing exercise as therapy in chronic disease. Scand J Med Sci Sport. 2006;16(S1):3-63.

Singh D. Effect of Cigarette Smoking on Serum Lipid Profile in Male Population of Udaipur. Biochem Anal Biochem. 2016;5(3):283.

Daoud E, Bergdahl SC, Bergdahl A. Effects of Dietary Macronutrients on Plasma Lipid Levels and the Consequence for Cardiovascular Disease. J Cardiovasc Dev Dis. 2014;1(3):201-13.

Scherer DJ, Nicholls SJ. Lowering triglycerides to modify cardiovascular risk: will icosapent deliver. Vasc Health Risk Manag. 2015;11:203-9.

Hunninghake DB, Stein EA, Bays HE. Rosuvastatin improves the atherogenic and athero protective lipid profiles in patients with hypertriglyceridemia. Coron Artery Dis. 2004;15(2):115-23.

Harris WS, Connor WE, Illingworth DR, Rothrock DW, Foster DM. Effects of fish oil on VLDL triglyceride kinetics in humans. J Lipid Res. 1990;31(9):1549-58.

Zahorcsek Z, Schneider I, Hortobagyi J. Successful treatment of eruptive xanthomatosis with the antilipemic agents acipimox. Hautarzt. 1995;46(2):124-6.

Kashif M, Kumar H, Khaja M. An unusual presentation of eruptive xanthoma: a case report and literature review. Med United States. 2016;95(37).

Laftah Z, Niaimi AF. Xanthelasma: an update on treatment modalities. J Cutan Aesthet Surg. 2018;11(1):1-6.

Nair PA, Singhal R. Xanthelasma palpebrarum: a brief review. Clin Cosmet Investig Dermatol. 2018;11:1-5.

Toor A, Toor A, Khalighi K, Krishnamurthy M. Case Report Triglyceride Levels Greater Than 10,000 mg/dL in a 49 years old female without Evidence of Pancreatitis. 2019.

Poonuru S, Pathak SR, Vats HS, Pathak RD. Rapid reduction of severely elevated serum. Clin Med Res. 2011;9(1):38-41.

Irie S, Anno T, Kawasaki F. Severe hypertriglyceridemia in a subject with disturbed life style and poor glycemic control without recurrence of acute pancreatitis: A case report. BMC Endocr Disord. 2019;19(1):92.